SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.0649-0.2%Nov 14 3:58 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Howard Williams6/11/2013 8:28:31 AM
1 Recommendation

Recommended By
Jack Russell

  Read Replies (1) of 13111
 
PV-10 Moves Forward
Tuesday June 11, 2013
A white paper titled "PV-10 Moves Forward" explores evidence of a systemic immune response induced by intralesional PV-10 injections, how local treatment evokes specific immune response leading to transferable immunity, and why PV-10 is favorable for combination therapy.

The white paper is available from the Provectus website at www.pvct.com/publications/Moffitt_post-AACR_whitepaper-6-10-13.pdf.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News